ArticleJournal of the American Association for Laboratory Animal Science : JAALAS2026
Efficacy and Pharmacokinetics of 3 Sustained-Release Buprenorphine Formulations in Cairo Spiny Mice (Acomys cahirinus).
Article in Journal of the American Association for Laboratory Animal Science : JAALAS, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
African spiny mice (Acomys spp.) are an emerging animal model for regeneration due to their remarkable healing capabilities. Defining characteristics of these species include fragile skin that sloughs easily and shedding of the tail skin when grabbed, making handling and administration of parenteral drugs difficult in conscious animals. In addition, many studies in spiny mice involve painful procedures. To our knowledge, there are no reports regarding analgesia in Acomys spp. This prospective study aimed to assess 3 sustained-release buprenorphine formulations-lipid-bound extended-release buprenorphine (XRB), polymeric sustained-release buprenorphine (SRB), and long-acting transdermal buprenorphine (TB)-in spiny mice. Adult male and female Cairo spiny mice (Acomys cahirinus) were included and administered 1 of the 3 treatments (XRB 3.25 mg/kg, SRB 1 mg/kg, or TB 20 mg/kg). Tail flick assays to assess nociception and terminal blood collection for pharmacokinetic analysis were performed at baseline and a set timepoint following treatment administration (1, 2, 4, 8, 24, 48, and 72 hours) (n = 3 of each sex per timepoint per treatment group). Additional animals underwent repeated serial tail flick assays at 1, 2, 4, 8, 24, 48, and 72 hours following the administration of treatment or sterile saline (n = 5-8 of each sex per treatment group). XRB displayed the longest duration at which mean plasma buprenorphine concentrations were >1 ng/mL, with the drug remaining above this level for 48-72 hours, compared with 24-48 hours in spiny mice receiving TB and 8 hours in those receiving SRB. On serial tail flick assays, the mean percentage of maximum possible efficacy was highest at all timepoints up to 72 hours in the TB group, followed by the XRB group, suggestive of greater analgesic efficacy. Several spiny mice receiving SRB developed ulcerative skin lesions within 24 hours of administration, so this treatment is not recommended in Acomys without additional evaluation. XRB and TB are promising analgesic therapies in spiny mice, and treatment selection should be based on whether duration of action or ease of application is the priority.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.